EXELIXIS, INC. (EXEL) Stock Profile — Insider Trades & Financials

Revenue$598.7M

Net Income$244.5M

EPS$2.78

Market Cap$11.4B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Michael M. Morrissey

CEO & Executive Director

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Employees: 954
Headquarters: ALAMEDA, CA, United States
Website: www.exelixis.com

Peer ComparisonRevenue ($B)

▾

⚡

Core Efficiency

ROE?

11.31%

ROA?

8.60%

D/E Ratio?

0.32

Op. Margin?

39.29%

📊

Profitability Ratios

Net Margin?

40.85%

Loading company sections...

EXELIXIS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness